Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POINT trial in high-risk TIA and minor ischemic stroke
ISRCTN73630073Phase 4Completed
- Sponsor
- University of California, San Francisco
- Start
- Jan 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
01
Overview
Phase 4, randomised, double-blind trial in transient ischaemic attack (TIA) and ischemic stroke comparing Clopidogrel plus aspirin with Placebo plus aspirin (2 arms). Primary endpoint: Prevention of major ischemic vascular events at 90 days. Started Jan 2014; status: completed.
02
Drugs
clopidogrelaspirin
03
Conditions
transient ischaemic attack (TIA)ischemic stroke
Beyond the preview
Go deeper on ISRCTN73630073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN73630073.